| HOME >> MEDICINE >> TECHNOLOGY |
(A)
$
4,020$ 23,874$ 21,051$
(205)
(A)
44,720Research and Development9,2917,441-16,73226,65124,471-51,122General and Administrative10,4218,934(4,531)
(B)
14,82427,46122,828(4,936)
(B)
45,353Total$ 27,839$ 22,473$
(4,736)$
45,576$ 77,986$ 68,350$
(5,141)$ 141,195(A) Selling and marketing included the following charges arising from the acquisition of TomoTherapy for the three and nine months ended March 31, 2011: $0.2 million primarily due to preparation for integration of work forces and operations.(B)
General and administration included the following charges arising from the acquisition of TomoTherapy for the three and nine months ended March 31, 2011: $4.5 million and $4.9 million due to preparation for integration of work forces and operations.Net Loss Attributableto StockholdersThree Months Ended March 31, 2011Nine Months Ended March 31, 2011AccurayTomoAdjustmentsCombinedAccurayTomoAdjustmentsCombinedLoss From Operations$
(526)$ (9,664)$
4,736$
(5,454)$ (2,970)$ (33,666)$
5,141$ (31,495)Other Income (Expense)221,927-1,9492,3143,714-6,028Provision For Income Taxes656753-1,4091,046929-1,975Noncontrolling Interest-(1,325)-(1,325)-(5,393)-(5,393)Net Loss Attributable to Stockholders$ (1,160)$ (7,165)$
4,736$
(3,589)$ (1,702)$ (25,488)$
5,141$ (22,049)Net Loss Per Share - Basic and Diluted$
(0.02)$
(0.13)$
(0.05)$
(0.03)$
(0.48)$
(0.32)Weighted Average Common Shares outstanding - Basic and Diluted59,96053,12569,073(C)59,29852,65268,411 (C) (C)
Represents weighted average common shares outstanding used to compute our basic and diluted net loss per share as disclosed in our Form 10Q for the three and nine months ended March 31, 2011, adjusted to reflect the acquisition of TomoTherapy as if it occurred on July 1, 2010.
| SOURCE Accuray Incorporated Copyright©2010 PR Newswire. All rights reserved |